Other phases 3 studies are ongoing in patients with untreated advanced CCA harbouring FGFR2 rearrangements to evaluate the efficacy of infigratinib (NCT03773302) and futibatinib (NCT04093362) vs. gemcitabine plus cisplatin chemotherapy in first-line treatment. The gene discussed is FGFR2; the disease is cholangiocarcinoma.